Key result
A newly developed LC-MS-MS method successfully quantified lercanidipine and valsartan in human plasma with high precision and recoveries of 98-103% in a pharmacokinetic study.
A new LC-MS-MS method was successfully developed and validated for the simultaneous quantification of lercanidipine and valsartan in human plasma for pharmacokinetic studies.
Answers are grounded in this paper and cite their sources.
Supports simultaneous PK studies of lercanidipine and valsartan; leaves open clinical translation pending further validation.
A simple, sensitive and reproducible liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-MS-MS) method was developed and validated for the first time for simultaneous quantification of lercanidipine and valsartan in human plasma. The analytes were extracted by simple protein precipitation with acetonitrile and separated on a Hanbon Hedera ODS-2 C18 (150 mm× 2.1 mm, 5 μm) column. The mobile phase was composed of a mixture (53:47, v/v) of acetonitrile and 10 mmol/L ammonium acetate containing 0.5% formic acid. The analytes were ionized by positive electrospray ion and detected in the multi-reaction monitoring mode with m/z 612.1 → 280.2 for lercanidipine, m/z 436.0 → 235.1 for valsartan and m/z 285.1 → 193.1 for diazepam, the internal standard. The calibration curves obtained were linear over the concentration range of 0.01504-10.07 ng/mL for lercanidipine and 5.025-6,030 ng/mL for valsartan. The results of the intra- and inter-day precision studies were within the acceptance range. The recoveries of the analytes were in the range of 98-103%. This method was successfully applied to the pharmacokinetic study of a novel fixed-dose combination of lercanidipine and valsartan formulation after an oral administration to healthy Chinese subjects.
No takes yet. Share an insight, caveat, or question.
Sabi-mouka et al. (2016) studied Healthy. Fixed-dose combination of lercanidipine and valsartan was evaluated on Quantification of lercanidipine and valsartan in human plasma. A newly developed LC-MS-MS method successfully quantified lercanidipine and valsartan in human plasma with high precision and recoveries of 98-103% in a pharmacokinetic study.
Synapse has enriched 10 related papers. Consider them for comparative context: